Highlights
- •Newly approved immune checkpoint inhibitors (ICI) enrich options for GEJ/GC therapies.
- •Relevant phase II/III trials focus on important biomarkers including PD-L1 assessment.
- •Next research may clarify ICI resistance mechanisms and varied gender responses.
Abstract
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerReferences
- Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.Eur J Cancer. 2018; 103: 356-387https://doi.org/10.1016/j.ejca.2018.07.005
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010; 376: 687-697https://doi.org/10.1016/S0140-6736(10)61121-X
- Novel HER2-directed treatments in advanced gastric carcinoma: AnotHER paradigm shift?.Cancers. 2021; 13: 1664https://doi.org/10.3390/cancers13071664
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.Lancet Oncol. 2019; 20: 827-836https://doi.org/10.1016/S1470-2045(19)30088-9
- Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (Pts) with advanced/metastatic HER2+ gastric cancer (GC)/Gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.J Clin Orthod. 2022; 40 (295–295)https://doi.org/10.1200/JCO.2022.40.4_suppl.295
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.Lancet Oncol. 2020; 21: 1066-1076https://doi.org/10.1016/S1470-2045(20)30326-0
- Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/− chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).J Clin Orthod. 2021; 39 (TPS264–TPS264)https://doi.org/10.1200/JCO.2021.39.3_suppl.TPS264
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.Lancet. 2021; 398: 27-40https://doi.org/10.1016/S0140-6736(21)00797-2
- Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.Nature. 2022; 603: 942-948https://doi.org/10.1038/s41586-022-04508-4
- Sex differences in immune responses.Nat Rev Immunol. 2016; 16: 626-638https://doi.org/10.1038/nri.2016.90
- Gender medicine and oncology: report and consensus of an ESMO workshop.Ann Oncol. 2019; 30: 1914-1924https://doi.org/10.1093/annonc/mdz414
- ATTRACTION-04 (ONO-4538-37): a randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer.Ann Oncol. 2017; 28: v266https://doi.org/10.1093/annonc/mdx369.159
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).Ann Oncol. 2019; 30: 250-258https://doi.org/10.1093/annonc/mdy540
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.Lancet. 2021; 398: 759-771https://doi.org/10.1016/S0140-6736(21)01234-4
- Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial.JAMA Oncol. 2020; 6: 1571-1580https://doi.org/10.1001/jamaoncol.2020.3370
- Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: update from the phase 3 KEYNOTE-062 trial.J Clin Orthod. 2022; 40 (243–243)
- KEYNOTE-859: a phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.Future Oncol. 2021; 17: 2847-2855https://doi.org/10.2217/fon-2021-0176
- Results of the JAVELIN gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).J Clin Orthod. 2020; 38 (278–278)https://doi.org/10.1200/JCO.2020.38.4_suppl.278
- LBA53 sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study.Ann Oncol. 2021; 32: S1331https://doi.org/10.1016/j.annonc.2021.08.2133
BeiGene announces positive findings from phase 3 trial of tislelizumab in combination with chemotherapy in first-line gastric or gastroesophageal junction cancer. Available online: https://www.businesswire.com/news/home/20220124005223/en/BeiGene-Announces-Positive-Findings-from-Phase-3-Trial-of-Tislelizumab-in-Combination-with-Chemotherapy-in-First-Line-Gastric-or-Gastroesophageal-Junction-Cancer [accessed on 08.08.22].
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.Lancet. 2018; 392: 123-133https://doi.org/10.1016/S0140-6736(18)31257-1
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.Lancet Oncol. 2019; 20: 1109-1123https://doi.org/10.1016/S1470-2045(19)30458-9
- RAP: a phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the Arbeitsgemeinschaft Internistische Onkologie (AIO).J Clin Orthod. 2019; 37 (TPS4148–TPS4148. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS4148)
- Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).J Clin Orthod. 2022; 40 (4051–4051. https://doi.org/10.1200/JCO.2022.40.16_suppl.4051)
- PRODIGE 59-DURIGAST trial: a randomised phase II study evaluating FOLFIRI + durvalumab ± tremelimumab in second-line of patients with advanced gastric cancer.Dig Liver Dis. 2021; 53: 420-426https://doi.org/10.1016/j.dld.2020.11.036
- The PRODIGE 59-DURIGAST trial: a randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.J Clin Orthod. 2022; 40 (4036–4036. https://doi.org/10.1200/JCO.2022.40.16_suppl.4036)
- KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (Pembro) monotherapy in patients with previously treated advanced gastric cancer.J Clin Orthod. 2017; 35 (4003–4003. https://doi.org/10.1200/JCO.2017.35.15_suppl.4003)
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 390: 2461-2471https://doi.org/10.1016/S0140-6736(17)31827-5
- Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN gastric 300.Ann Oncol. 2018; 29: 2052-2060https://doi.org/10.1093/annonc/mdy264
- INTEGRATE IIb: a randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).J Clin Orthod. 2022; 40 (TPS366–TPS366)https://doi.org/10.1200/JCO.2022.40.4_suppl.TPS366
- CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer.J Clin Oncol. 2018; 36: 2836-2844https://doi.org/10.1200/JCO.2017.76.6212
- Oligometastases.J Clin Oncol. 1995; 13: 8-10https://doi.org/10.1200/JCO.1995.13.1.8
- Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.N Engl J Med. 2021; 384: 1191-1203https://doi.org/10.1056/NEJMoa2032125
- Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.Eur J Cancer. 2022; 164: 18-29https://doi.org/10.1016/j.ejca.2021.11.032
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.Lancet Oncol. 2020; 21: 821-831https://doi.org/10.1016/S1470-2045(20)30169-8
- Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study.J Clin Orthod. 2021; 39 (4013–4013)https://doi.org/10.1200/JCO.2021.39.15_suppl.4013
- Ipilimumab or FOLFOX with nivolumab and trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric adenocarcinoma – the randomized phase 2 INTEGA trial (AIO STO 0217).BMC Cancer. 2020; : 20https://doi.org/10.1186/s12885-020-06958-3
- Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial.JAMA Oncol. 2022; https://doi.org/10.1001/jamaoncol.2022.2228
- A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).J Clin Orthod. 2021; 39 (TPS261–TPS261. https://doi.org/10.1200/JCO.2021.39.3_suppl.TPS261)
- 1379P margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A.Ann Oncol. 2021; 32: S1043-S1044https://doi.org/10.1016/j.annonc.2021.08.1488
A Phase 1 clinical study to investigate the safety and pharmacokinetics of tucatinib (MK-7119) in China participants with HER2+ advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma and colorectal cancer – AdisInsight Available online: https://adisinsight.springer.com/trials/700352320 [accessed on 31.07.22].
- P-26 HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA).Ann Oncol. 2022; 33: S256https://doi.org/10.1016/j.annonc.2022.04.117
- Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).Eur J Cancer. 2018; 105: 41-49https://doi.org/10.1016/j.ejca.2018.09.024
- ESMO guidelines committee gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2016; 27: v38-v49https://doi.org/10.1093/annonc/mdw350
- Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2016; 27: v50-v57https://doi.org/10.1093/annonc/mdw329
- de ESMO-Magnitude of clinical benefit scale Version 1.1.Ann Oncol. 2017; 28: 2340-2366https://doi.org/10.1093/annonc/mdx310
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.Nature. 2021; 600: 727-730https://doi.org/10.1038/s41586-021-04161-3
- Comprehensive molecular characterization of gastric adenocarcinoma.Nature. 2014; 513: 202-209https://doi.org/10.1038/nature13480
- Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies.Oncol Lett. 2020; 19: 3665-3670https://doi.org/10.3892/ol.2020.11520
- FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.Ann Oncol. 2021; 32: 609-619https://doi.org/10.1016/j.annonc.2021.02.005
- GLOW: randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.Ann Oncol. 2019; 30: v322https://doi.org/10.1093/annonc/mdz247.162
- SPOTLIGHT: comparison of zolbetuximab or placebo + MFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): a randomized phase III study.Ann Oncol. 2019; 30: ix66-ix67https://doi.org/10.1093/annonc/mdz422.074
- Trial in progress: phase 3 study of bemarituzumab + MFOLFOX6 versus placebo + MFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101).J Clin Orthod. 2022; 40 (TPS4164–TPS4164. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4164)
- Trial in progress: phase 1b/3 study of bemarituzumab + MFOLFOX6 + nivolumab versus MFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102).J Clin Orthod. 2022; 40 (TPS4165–TPS4165. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4165)
- Overview of Epstein-Barr-virus-associated gastric cancer correlated with prognostic classification and development of therapeutic options.Int J Mol Sci. 2020; 21: E9400https://doi.org/10.3390/ijms21249400
- Immune activation and benefit from avelumab in EBV-positive gastric cancer.J Natl Cancer Inst. 2017; 110: 316-320https://doi.org/10.1093/jnci/djx213
- High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.Pathol Res Pract. 2020; 216152881https://doi.org/10.1016/j.prp.2020.152881
- Helicobacter pylori in gastric cancer: features of infection and their correlations with long-term results of treatment.World J Gastroenterol. 2021; 27: 6290-6305https://doi.org/10.3748/wjg.v27.i37.6290
- Global burden of gastric cancer attributable to Helicobacter pylori.Int J Cancer. 2015; 136https://doi.org/10.1002/ijc.28999
- Helicobacter pylori and gastric cancer: a state of the art review.Gastroenterol Hepatol Bed Bench. 2015; 8: S6-S14
- Effects of Helicobacter pylori on tumor microenvironment and immunotherapy responses.Front Immunol. 2022; 13
- Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score ≥10.Clin Cancer Res. 2021; 27: 1923-1931https://doi.org/10.1158/1078-0432.CCR-20-2980
- Low programmed death-ligand 1–expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma.J Clin Orthod. 2022; 40: 392-402https://doi.org/10.1200/JCO.21.01862
- Association of magnitude and consistency of PD-L1 expression and other variables associated with benefit from immune checkpoint inhibition (ICI): systematic review and meta-analysis of 14 phase 3 trials in advanced gastroesophageal cancer (GEC).J Clin Orthod. 2022; 40 (344–344. https://doi.org/10.1200/JCO.2022.40.4_suppl.344)
- Predictive value of PD-L1 diagnostics.Pathologe. 2018; 39: 498-519https://doi.org/10.1007/s00292-018-0507-x
- Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials.ESMO Open. 2021; 6https://doi.org/10.1016/j.esmoop.2020.100036
- MSI-GC-01: individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).J Clin Orthod. 2019; 37 (66–66. https://doi.org/10.1200/JCO.2019.37.4_suppl.66)
- 1429P pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: results from the DANTE trial of the German gastric group at the AIO and SAKK.Ann Oncol. 2021; 32: S1069https://doi.org/10.1016/j.annonc.2021.08.1538
- Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (Pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (DMMR) oeso-gastric adenocarcinoma (OGA): the GERCOR NEONIPIGA phase II study.J Clin Orthod. 2022; 40 (244–244 https://doi.org/10.1200/JCO.2022.40.4_suppl.244)
- Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.Gastric Cancer. 2021; 24: 823-834https://doi.org/10.1007/s10120-021-01175-8
- The association of tissue tumor mutational burden (TTMB) using the foundation medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (Pts) with gastric cancer (GC) from KEYNOTE-061.J Clin Orthod. 2020; 38 (4537–4537. https://doi.org/10.1200/JCO.2020.38.15_suppl.4537)
- Pembrolizumab (Pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.J Clin Orthod. 2020; 38 (4523–4523 https://doi.org/10.1200/JCO.2020.38.15_suppl.4523)
- 1443P modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – safety results from AIO-STO-0417: a randomized phase II trial of the German gastric group of the AIO.Ann Oncol. 2020; 31: S908https://doi.org/10.1016/j.annonc.2020.08.1949
- Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma.Transl Cancer Res. 2022; 11: 193-205https://doi.org/10.21037/tcr-21-1601
- CD155T/TIGIT signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer.Cancer Res. 2017; 77: 6375-6388https://doi.org/10.1158/0008-5472.CAN-17-0381
- CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells.Immunity. 2020; 53: 805-823.e15https://doi.org/10.1016/j.immuni.2020.09.010
- Phase I trial of claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.J Clin Orthod. 2019; 37 (2509–2509. https://doi.org/10.1200/JCO.2020.38.15_suppl.4523)
- Claudin18.2-Specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.Nat Med. 2022; 28: 1189-1198https://doi.org/10.1038/s41591-022-01800-8